NEW YORK (Reuters) - U.S. regulators have concluded that GlaxoSmithKline's (GSK.L: Quote, Profile, Research) Requip CR extended-release tablets to treat moderate-to-severe primary restless legs syndrome must meet additional conditions before getting final approval, the company said on Friday.